Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

• Published in: Diabetes, obesity & metabolism Vol. 24; no. 9; pp. 1840 - 1849
• Main Authors: Piemonti, Lorenzo, Keymeulen, Bart, Gillard, Pieter, Linn, Thomas, Bosi, Emanuele, Rose, Ludger, Pozzilli, Paolo, Giorgino, Francesco, Cossu, Efisio, Daffonchio, Luisa, Goisis, Giovanni, Ruffini, Pier Adelchi, Maurizi, Anna Rita, Mantelli, Flavio, Allegretti, Marcello
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2022; Wiley Subscription Services, Inc
• Subjects: beta cell function; Beta cells; Chemokine receptors; Clinical trials; CXCR2 protein; Diabetes; Diabetes mellitus (insulin dependent); Double-blind studies; Inhibitor drugs; Insulin; Patients; Peptides; phase I‐II study; Placebos; randomized trial; type 1 diabetes

Aim To evaluate the ability of ladarixin (LDX, 400 mg twice‐daily for three cycles of 14 days on/14 days off), an inhibitor of the CXCR1/2 chemokine receptors, to maintain C‐peptide production in adult patients with newly diagnosed type 1 diabetes. Materials and Methods A double‐blind, randomized (2...